PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26023F0351Arcalyst rilonacept 220mg VIL INJ — Kiniksa Pharmaceuticals (Uk), Ltd

Kiniksa Pharmaceuticals (Uk), Ltd holds $1.2M across 22 federal awards, concentrated at Department of Veterans Affairs (VA). This PIID sits alongside 1 related award under parent 36F79722D0002. The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended May 31, 2024 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

260-Network Contract Office 20 (36C260)
Awarding office
Kiniksa Pharmaceuticals (Uk), Ltd
Recipient
May 31, 2024
PoP end
$170K
Obligated
$196K
Potential
325412
NAICS
6505
PSC
1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Kiniksa Pharmaceuticals (Uk), Ltd — $90

Contract facts

Federal
Contract number36C26023F0351
Also listed as36C260-23-F-0351
Also listed as36F79722D0002-36C26023F0351
Agency260-Network Contract Office 20 (36C260)
Awarding office260-Network Contract Office 20 (36C260)
Awarding agencyDepartment of Veterans Affairs (VA)
Funding agencyDepartment of Veterans Affairs (VA)
IncumbentKiniksa Pharmaceuticals (Uk), Ltd
CAGEU1S38
UEIHBHWNLNMHSV5
NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505
Parent IDIQ / IDV36F79722D0002
Place of performanceSEATTLE WA
Pricing typeFirm Fixed Price
Extent competedFull And Open Competition
PoP startJun 1, 2023
PoP end (current)May 31, 2024
Obligated$170K
Current value$196K
Potential value$196K

RILONACEPT (ARCALYST) 220MG/VIL INJ is a federal award for 260-Network Contract Office 20 (36C260) held by Kiniksa Pharmaceuticals (Uk), Ltd. Estimated value $196K ($170K obligated). Current period of performance ends May 31, 2024. Last award drew 1 bidder. Place of performance: SEATTLE WA.

Recompete timing

Public
Past PoP end (812 days ago)

Current PoP ended May 31, 2024 (812 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Kiniksa Pharmaceuticals (Uk), Ltd$1.2M obligated across 22 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).

% of firm-wide obligated ($1.2M) · all agencies
Department of Veterans Affairs (VA)$942K · 79%Department of Justice (DOJ)$269K · 22%
Open full company profile

Related awards

Same parent · incumbent
36C26026F0076
BULK - ARCALYST 220MG VIL
$220K
Dec 14, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

More in SCOUT
Size up the competition →Research the incumbent →

Frequently asked questions

What is contract 36C26023F0351?

36C26023F0351 (Arcalyst rilonacept 220mg VIL INJ) is a 260-Network Contract Office 20 (36C260) award with a potential value of $196K, currently held by Kiniksa Pharmaceuticals (Uk), Ltd. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C260-23-F-0351?

36C260-23-F-0351 is the dashed form of PIID 36C26023F0351 (Arcalyst rilonacept 220mg VIL INJ), held by Kiniksa Pharmaceuticals (Uk), Ltd. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26023F0351?

260-Network Contract Office 20 (36C260) awarded 36C26023F0351 to Kiniksa Pharmaceuticals (Uk), Ltd (potential $196K).

Who is the incumbent on 36C26023F0351?

Kiniksa Pharmaceuticals (Uk), Ltd is the incumbent with $1.2M across 22 related awards in SCOUT’s public footprint. The current period of performance ends May 31, 2024.

When does Kiniksa Pharmaceuticals (Uk), Ltd’s 36C26023F0351 come up for recompete?

SCOUT tracks a period-of-performance end of May 31, 2024. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/36C26023F0351